IP Library › Patent Application 15293011
Patent Application
App. No. 15/293,011

IMMUNOTHERAPY OF CANCER USING GENETICALLY ENGINEERED GD2-SPECIFIC T CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/293,011
Abstract

The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).

Claims (8)

1 . A method of targeting a cancer cell having a GD2 antigen, comprising the steps of providing to the cell a cytotoxic T lymphocyte with a chimeric receptor that recognizes the GD2 antigen.

2 . The method of claim 1 , wherein the cancer cell is in vitro or in vivo.

3 . The method of claim 1 , wherein the chimeric receptor comprises antibody that binds GD2

4 . The method of claim 2 , wherein the antibody is a scFv antibody.

5 . The method of claim 2 , wherein the antibody is the 14g2a scFv antibody.

6 . The method of claim 1 , wherein the chimeric receptor comprises the effector domain of the T-cell receptor zeta chain or related signal transduction endodomains derived from the T cell receptor.

7 . The method of claim 1 , wherein the chimeric receptor comprises one or more costimulatory molecules.

8 . The method of claim 6 , wherein the costimulatory molecules comprise CD28, OX40, 4-1BB, or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2016
From: BRENNER, MALCOLM; DOTTI, GIANPIETRO; AHMED, NABIL; ROSSIG, CLAUDIA; GOTTSCHALK, STEPHEN M. G.; GRADA, ZAKARIA
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 040010/0227 →